Authors' reply to Alatorre et al.: "cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison"

Appl Health Econ Health Policy. 2013 Jun;11(3):307. doi: 10.1007/s40258-013-0025-1.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adrenergic Uptake Inhibitors / economics*
  • Adrenergic alpha-2 Receptor Agonists / economics*
  • Attention Deficit Disorder with Hyperactivity / economics*
  • Female
  • Guanfacine / economics*
  • Humans
  • Male
  • Propylamines / economics*

Substances

  • Adrenergic Uptake Inhibitors
  • Adrenergic alpha-2 Receptor Agonists
  • Propylamines
  • Guanfacine